Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293264 | 0.95 | BRPF1 (0.43) | BRPF1LMNAHTTSMN1; SMN2HDAC1 | |
| SCHEMBL10293049 | 0.90 | POLB (0.45) | BRPF1LMNAHTTSMN1; SMN2HDAC1 | |
| SCHEMBL10292588 | 0.89 | BRPF1 (0.45) | BRPF1CYP3A4SMN1; SMN2HDAC1KDM4E | |
| SCHEMBL10292589 | 0.88 | TP53 (0.42) | BRPF1HDAC1KDM4EBRD4 | |
| SCHEMBL10004164 | 0.86 | BRPF1 (0.47) | BRPF1LMNACYP3A4SMN1; SMN2HDAC1 | |
| SCHEMBL10292511 | 0.86 | BRPF1 (0.42) | BRPF1SMN1; SMN2HDAC1KDM4E | |
| SCHEMBL10293272 | 0.86 | BRPF1 (0.42) | BRPF1SMN1; SMN2HDAC1KDM4E | |
| SCHEMBL10292946 | 0.86 | BRPF1 (0.42) | BRPF1CYP3A4HTTSMN1; SMN2HDAC1 | |
| SCHEMBL10292619 | 0.86 | BRPF1 (0.42) | BRPF1LMNASMN1; SMN2HDAC1KDM4E | |
| SCHEMBL10293045 | 0.85 | HPGD (0.46) | BRPF1LMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486965-B2 | Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2471789-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220569-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | SMO, GLI1, SHH | NAMPT 970/4885BRPF1 1937/4885CCR8 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.